The tweet was deleted by the author.
But we saved everything 🙂.
Arcus Biosciences announced a clinical trial collaboration and supply agreement with BMS to evaluate casdatifan in advanced kidney cancer.
The agreement will test Arcus Biosciences' investigational HIF-2a inhibitor casdatifan in combination with a PD-L1/VEGF-A bispecific immunomodulator. The combination will be studied in the Phase 1/2 ROSETTA RCC-208 trial.
View post on X Loading...
RCUS is currently trading at $24.47, slightly below the MA-20 ($24.55) but above the MA-50 ($23.75) and well above the MA-200 ($20.16). This setup indicates near-term pressure from sellers, while the medium- and long-term structure remains bullish with strong upward support from the longer moving averages. The Ichimoku Kijun sits at $24.66, acting as immediate resistance for the price. Near-term support is seen at MA-50 ($23.75), with key support at MA-100 ($22.68). Immediate resistance is the Kijun ($24.66), while MA-20 ($24.55) serves as near-term resistance and MA-200 ($20.16) as key longer-term support.
Momentum on D1 is mixed, with a buy signal from MACD but a low ADX (10.19) indicating a weak trend. RSI is balanced at 50.78, while Stoch RSI signals strong sell conditions, and CCI remains neutral. BBP flags an overbought environment, highlighting short-term buyer dominance, but there is divergence among oscillators. The Awesome Oscillator supports the current bullish undertone. In today's session, RCUS is down 4.67% following a $1.20 loss against the previous close, signaling increased near-term volatility. Over the past week, the stock has declined $0.87 (3.43%) from $25.34, currently trading in the lower part of the weekly range. Weekly volatility stands at 11.37%. The persistent retreat from the weekly high suggests a steady decline with heightened pressure from sellers.
Looking ahead, the expected price corridor for the next week is $24.20 to $25.25, keeping the range tight and realistic based on current volatility and recent levels. On the W1 timeframe, all trend indicators (MA-50, RSI, ADX, MACD) point to sustained bullishness, setting the probability of an upside move at more than 80% and making a decline less likely. The baseline scenario expects RCUS to consolidate between $24.20 and $25.25 as it digests recent volatility. If bulls push through immediate resistance at $24.66, a move toward the upper end of the range is plausible. Conversely, failure to hold support at $23.75 could trigger a test of the lower band. This weekly range keeps RCUS well above its 52-week low of $7.91 and just below the yearly peak of $28.72, reflecting continued outperformance on a longer-term basis.